Skip to main content
Clinical Trials/NCT03384888
NCT03384888
Unknown
Not Applicable

Neurostimulation Applied to Fibromyalgia

Federal University of Paraíba1 site in 1 country59 target enrollmentMay 15, 2017
ConditionsFibromyalgia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fibromyalgia
Sponsor
Federal University of Paraíba
Enrollment
59
Locations
1
Primary Endpoint
Pain intensity level
Last Updated
7 years ago

Overview

Brief Summary

NeuroFibro is a double-blind, randomized, placebo-controlled clinical trial, using neurostimulation in women with fibromyalgia.

Registry
clinicaltrials.gov
Start Date
May 15, 2017
End Date
May 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Federal University of Paraíba
Responsible Party
Principal Investigator
Principal Investigator

Géssika Araújo de Melo

Eliane Araújo de Oliveira

Federal University of Paraíba

Eligibility Criteria

Inclusion Criteria

  • (1) diagnosis of fibromyalgia, according to the American College of Rheumatology criteria;
  • (2) been diagnosed for at least three months;
  • (3) be female;
  • (4) be in the age group between 25 and 60 years of age; and
  • (5) sign the consent form.

Exclusion Criteria

  • (1) cognitive deficit, evaluated through the Mini Mental State Examination (MMSE);
  • (2) illiterate;
  • (3) people with metallic implants located on the head, cochlear implants and cardiac pacemaker;
  • (4) history of convulsion;
  • (5) severe depression, measured by score greater than 36 on Beck Depression Inventory; and
  • (6) be pregnant.

Outcomes

Primary Outcomes

Pain intensity level

Time Frame: Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)

Changes in pain level, assessed by the Visual Analog Scale, ranges from 0 - 10, with 10 being the highest level of pain.

Secondary Outcomes

  • Quality of life level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Anxiety level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Depression level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Cognitive function(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Cortical electrical activity(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Health assessment level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Sleep quality(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
  • Resilience(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))

Study Sites (1)

Loading locations...

Similar Trials